Kirsten Carr Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2019 E Front St, Logan, OH 43138 Phone: 740-385-1171 |
Vanessa Mae Judy, M.A. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 300 Arlington Ave, Logan, OH 43138 Phone: 740-385-2155 |
Tabitha Mccloud Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 11620 Highland Park, Logan, OH 43138 Phone: 740-590-9412 Fax: 614-420-2896 |
Megan Fowler, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1 Middleschool Dr, Logan, OH 43138 Phone: 740-385-8764 |
Mrs. Stacie Dawn Vecchiarelli, M.A.CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8864 State Route 664 N, Logan, OH 43138 Phone: 740-603-5228 Fax: 740-385-3848 |
Mrs. Laurie Cummings Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 445 N Market St, Logan, OH 43138 Phone: 740-380-4664 |
Speech On The Spot Se Ohio Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11620 Highland Park, Logan, OH 43138 Phone: 740-590-9412 |
News Archive
On Friday, the American Medical Group Association (AMGA) drafted and submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) regarding the proposed rule on refinements to the current framework of the Medicare Shared Savings Program.
Nine in 10 primary care physicians say that prescription drug abuse is a moderate or big problem in their communities and nearly half say they are less likely to prescribe opioids to treat pain compared to a year ago, new Johns Hopkins Bloomberg School of Public Health research suggests.
A new study in the Journal of Adolescent Health finds that the sexual risk behaviors of young Hispanic people living in the U.S. vary considerably with their degree of acculturation (as defined by where they were born and the language they speak).
Quoting Mike Snowden (VP & Head of Discovery Sciences, AstraZeneca), "it's where biology meets chemistry". It's where for the first time a target protein can be probed for novel molecules that modulate its function, of course we want to do this to prove a hypothesis that these proteins are drug targets with the potential to deliver innovative medicines.
Sesen Bio, Inc., a late-stage clinical company developing fusion protein therapies for the treatment of cancer, today announced that the company will present its three-month Phase 3 VISTA Trial data during a poster session at the Global Congress on Bladder Cancer 2018.
› Verified 3 days ago